Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b/3 randomized double-blind placebo-controlled study of MK-1654 for prevention of RSV in healthy pre-term and full-term infants
2020-002405-26Phase 2
- Sponsor
- Merck & Co.
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) and respiratory syncytial virus bronchiolitis comparing MK-1654 with Placebo (2 arms). Primary endpoint: Percentage of participants with RSV-associated medically attended lower respiratory infection (MALRI).
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus disease (RSV)respiratory syncytial virus bronchiolitis
Beyond the preview
Go deeper on 2020-002405-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002405-26.